182.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Why (AXSM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Axsome Therapeutics (AXSM) Stock Analysis: A 63% Revenue Growth Fuels a Promising Biotech Play - DirectorsTalk Interviews
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN
Should You Buy Axsome Therapeutics Stock Before Feb. 23? - AOL.com
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM) - Sahm
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics Stock Soars 75% Amid Strong Growth - Intellectia AI
Principal Financial Group Inc. Acquires 12,923 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer’s Label Hopes - Yahoo Finance
Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN
1 High-Flying Stock With More Upside Ahead - Finviz
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates - Finviz
Axsome Therapeutics (NASDAQ:AXSM) Given New $245.00 Price Target at Jefferies Financial Group - MarketBeat
Axsome Therapeutics (AXSM) reports 66% revenue growth in FY2025, beats analyst estimates - MSN
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: Strong Buy Ratings and Promising 15.71% Potential Upside - DirectorsTalk Interviews
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $6,015,296.00 in Stock - MarketBeat
Axsome Therapeutics CEO Tabuteau sells $6.0m in shares By Investing.com - Investing.com Canada
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says - marketscreener.com
Axsome Therapeutics stock maintains Outperform rating at RBC on ADA approval potential - Investing.com Canada
Understanding Momentum Shifts in (AXSM) - Stock Traders Daily
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy - Insider Monkey
J. Safra Sarasin Holding AG Has $1.08 Million Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM: Leerink Partners Raises Price Target to $205, Maintains Ou - GuruFocus
Leerink Partners Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Revenues Tell The Story For Axsome Therapeutics, Inc. (NASDAQ:AXSM) - 富途牛牛
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - Quiver Quantitative
Is Axsome Therapeutics Inc attractive for institutional investors2025 Volatility Report & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? - sharewise.com
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline (NASDAQ:AXSM) - Seeking Alpha
Ari Maizel, chief commercial officer of Axsome, sells $1.38m in shares By Investing.com - Investing.com Nigeria
Ari Maizel, chief commercial officer of Axsome, sells $1.38m in shares - Investing.com UK
Pizzie, Axsome Therapeutics CFO, sells $2.25m in shares By Investing.com - Investing.com Canada
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) Insider Sells 7,500 Shares of Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CFO Sells $2,255,040.00 in Stock - MarketBeat
How The New Price Target Is Shaping The Axsome Therapeutics (AXSM) Investment Story - Yahoo Finance
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM) - Barchart.com
Analysts Conflicted on These Healthcare Names: Hinge Health, Inc. Class A (HNGE), Axsome Therapeutics (AXSM) and TG Therapeutics (TGTX) - The Globe and Mail
Assessing Axsome Therapeutics (AXSM) Valuation After Analyst Upgrades And Pipeline Progress - Yahoo Finance
Axsome begins phase III AXS-14 Forward trial for fibromyalgia management - MSN
(01/23/26) Top Picks 2026: Axsome Therapeutics Inc. (AXSM) - moneyshow.com
Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30 - Insider Monkey
FY2025 Earnings Forecast for AXSM Issued By HC Wainwright - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):